Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular Responses

Brendan Wisniowski, MBBS, Sally Mapp, MBBS, PhD FRACP, FRCPA, Louise Knop, BSc (Hons), James Morton, MBBS, BSc(MD, FRACP, FRCPA, Paul Eliadis, FRACP,FRCPA,MBBS, Anthony K. Mills, MBBS, FRACP, FRCPA

Blood (2016) 128 (22): 5460.

https://doi.org/10.1182/blood.V128.22.5460.5460

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Low Dose Anti-Thymocyte Globulin (ATGAM) As Treatment of Aplastic Anaemia Is Associated with Similar Response Rates and Survival As per Higher Dose Atgam Schedules

Ashleigh Scott, MBBS, Anthony K. Mills, MBBS, FRACP, FRCPA, Kirk Lachlan Morris, FRACP,FRCPA,MBBS, MB, BS, Midori Nakagaki, BPharm, BCOP, Glen A Kennedy, MBBS, FRACP, FRCPA

Blood (2014) 124 (21): 4394.

https://doi.org/10.1182/blood.V124.21.4394.4394

Published: 2014

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA

Blood (2011) 118 (21): 451.

https://doi.org/10.1182/blood.V118.21.451.451

Published: 2011

Journal Articles

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Deborah L. White, PhD. FFSc(RCPA), Verity A Saunders, BScHons, Amity Frede, BScHons, Kelvin GrootObbink, BScHons, Cassandra Slader, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P Hughes, MD, MBBS

Blood (2011) 118 (21): 1690.

https://doi.org/10.1182/blood.V118.21.1690.1690

Published: 2011

Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2010) 116 (21): 209.

https://doi.org/10.1182/blood.V116.21.209.209

Published: 2010

Journal Articles

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Deborah L. White, PhD, Verity Saunders, Amity Frede, Kelvin GrootObbink, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 356.

https://doi.org/10.1182/blood.V116.21.356.356

Published: 2010

Journal Articles

Imatinib PK: Observations From the TIDEL II Study

Deborah L. White, PhD, Verity Saunders, Menelaou Andrew, Allan Rofe, PhD, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 2288.

https://doi.org/10.1182/blood.V116.21.2288.2288

Published: 2010

Journal Articles

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Melita K Kenealy, MBBS, FRACP, FRCPA, John F Seymour, MBBS, PhD, FRACP, Cowan Linda, Alvin Milner, Pratyush Giri, Shir-Jing Ho, MBBS, FRACP, FRCPA, Warwick Benson, Andrew Nicol, MBBS, FRCPA, FRACP, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Craig Underhill, MBBS, FRACP, Ilona Cunningham, Anthony K. Mills, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Peter Presgrave, MBBS, FRACP, FRCPA, PhD, Robin Filshie, MBChB, FRACP, FRCPA, PhD

Blood (2009) 114 (22): 1749.

https://doi.org/10.1182/blood.V114.22.1749.1749

Published: 2009

NARROW

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular Responses

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Low Dose Anti-Thymocyte Globulin (ATGAM) As Treatment of Aplastic Anaemia Is Associated with Similar Response Rates and Survival As per Higher Dose Atgam Schedules

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Imatinib PK: Observations From the TIDEL II Study

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only